Study of Bapineuzumab (AAB-001) Administered Subcutaneously At Monthly Intervals in Subjects with Mild to Moderate AD

Grants and Contracts Details

StatusFinished
Effective start/end date10/18/106/30/13

Funding

  • Janssen Alzheimer Immunotherapy Research and Development LLC: $16,772.00